- In 332,630 new cases of breast cancer, only 3% – 5% of patients participated in traditional clinical studies.
- RWE: “expected to allow for deeper insights and greater understanding of the variance of patient treatment outcomes”
- An initial two year contract focused on breast cancer, but there’s potential to explore other cancer epidemiology
Click here to see the source article
SVMPharma is an innovative strategic consultancy, specialising in Real World Evidence (RWE) for the pharmaceutical industry. SVMPharma generates RWE within UK and Europe through bespoke online Real World Treatment Evaluators, leading to successful health technology appraisal (HTA) submissions. Clinical trial programmes do not reflect real-world clinical practice and outcomes, RWE supplements and enhances clinical datasets. SVMPharma’s specialist teams focus on delivering the outcomes that matter to your brand.